Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis Howard Sofen, MD, Stacy.

Slides:

Advertisements

Similar presentations

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Advertisements

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology Saakshi Khattri, MD, Avner.

Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in.

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis Mayte Suárez-Fariñas, PhD,

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

The Editors' Choice Journal of Allergy and Clinical Immunology

Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Is 9 more than 2 also in allergic airway inflammation?

Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis Mutasem M. Rawas-Qalaji,

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,

Shinji Noda, MD, PhD, James G

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis Tali Czarnowicki, MD, Dana Malajian, BA, Avner Shemer,

Pathergy response to skin prick testing

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells Kristine E. Nograles, MD,

Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-γ–inducible protein 10 expression in asthmatic.

Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1–high T cells Jong Hoon.

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Yuichi Teraki, MD, Aika Sakurai, MD, Seiichi Izaki, MD

Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism Emma Guttman-Yassky, MD, PhD, Benjamin Ungar, BA, Shinji Noda, MD, PhD, Maria.

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized,

Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis Shunya Mashiko, BPharm, Salim Bouguermouh, MD, PhD, Manuel.

Effective Narrow-Band UVB Radiation Therapy Suppresses the IL-23/IL-17 Axis in Normalized Psoriasis Plaques Leanne M. Johnson-Huang, Mayte Suárez-Fariñas,

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis Yuichi Teraki, MD, Misaki Kawabe, MD, Seiichi.

Thymic stromal lymphopoietin–activated invariant natural killer T cells trigger an innate allergic immune response in atopic dermatitis Wen Hao Wu, PhD,

Sabine Leisten, MSc, Michiko K

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

The Editors' Choice Journal of Allergy and Clinical Immunology

Journal of Allergy and Clinical Immunology

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo,

The Editors' Choice Journal of Allergy and Clinical Immunology

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Advances in the approach to the patient with food allergy

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

T cell–intrinsic prostaglandin E2-EP2/EP4 signaling is critical in pathogenic TH17 cell– driven inflammation Jinju Lee, MSc, Tomohiro Aoki, MD, PhD, Dean.

Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in.

Journal of Allergy and Clinical Immunology

News Beyond Our Pages Journal of Allergy and Clinical Immunology

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Xiu-Min Li, MD, LaVerne Brown, PhD

Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis Eva Gros, MSc, Caroline Bussmann,

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Alan Menter, MD, Stephen K

Complete DiGeorge syndrome: Development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases M Louise Markert, MD, PhD, Marilyn J Alexieff, BA,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression Atsushi Otsuka, MD, PhD, Hiromi Doi, MS, Gyohei.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitis Janine Bilsborough, PhD, Donald.

Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response Meri K Tulic, PhD, Pierre-Olivier Fiset,

Immunopathology of atopic dermatitis

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Presentation transcript:

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis Howard Sofen, MD, Stacy Smith, MD, Robert T. Matheson, MD, Craig L. Leonardi, MD, Cesar Calderon, PhD, Carrie Brodmerkel, PhD, Katherine Li, MS, Kim Campbell, PhD, Stanley J. Marciniak, MBA, Yasmine Wasfi, MD, PhD, Yuhua Wang, PhD, Philippe Szapary, MD, James G. Krueger, MD, PhD Journal of Allergy and Clinical Immunology Volume 133, Issue 4, Pages 1032-1040 (April 2014) DOI: 10.1016/j.jaci.2014.01.025 Copyright © 2014 The Authors Terms and Conditions

Fig 1 Proportion of patients achieving at least a 75% improvement in Psoriasis Area and Severity Index (PASI 75) response (A) or a PASI 90 response (B) from baseline to week 24. Journal of Allergy and Clinical Immunology 2014 133, 1032-1040DOI: (10.1016/j.jaci.2014.01.025) Copyright © 2014 The Authors Terms and Conditions

Fig 2 A, Clinical response to a single dose of 10 mg of guselkumab administered at baseline. B, Clinical response to a single dose of 300 mg of guselkumab administered at baseline. Journal of Allergy and Clinical Immunology 2014 133, 1032-1040DOI: (10.1016/j.jaci.2014.01.025) Copyright © 2014 The Authors Terms and Conditions

Fig 3 Histologic evaluation of nonlesional and lesional skin at baseline and week 12 after subcutaneous injection of 300 mg of guselkumab. CD3, T cell; CD11c, myeloid DC; H&E, hematoxylin and eosin; KRT16, keratin 16. Journal of Allergy and Clinical Immunology 2014 133, 1032-1040DOI: (10.1016/j.jaci.2014.01.025) Copyright © 2014 The Authors Terms and Conditions

Fig 4 Evaluation of mean epidermal thickness and T-cell (CD3) and myeloid DC (CD11c) expression from lesional skin biopsy specimens at baseline and after guselkumab or placebo treatment at weeks 1 and 12. Journal of Allergy and Clinical Immunology 2014 133, 1032-1040DOI: (10.1016/j.jaci.2014.01.025) Copyright © 2014 The Authors Terms and Conditions

Fig 5 A, Expression of KRT16, IFN-γ, IL-17F, and LCN2 mRNA at baseline and week 12 in lesional and nonlesional biopsy specimens from patients treated with high-dose (100 mg + 300 mg) guselkumab compared with placebo. B, Microarray expression of 1224 transcripts of nonlesional skin at baseline versus lesional skin at baseline and at weeks 1 and 12 after guselkumab treatment. Journal of Allergy and Clinical Immunology 2014 133, 1032-1040DOI: (10.1016/j.jaci.2014.01.025) Copyright © 2014 The Authors Terms and Conditions

Fig 6 Serum analyses of circulating IL-17A levels in guselkumab-treated responders (PASI 50 response at week 12) at baseline and at weeks 1 and 12 compared with the placebo-treated group. P values measure the significant difference in posttreatment compared with baseline values. *P = .031 and **P = .0015. Journal of Allergy and Clinical Immunology 2014 133, 1032-1040DOI: (10.1016/j.jaci.2014.01.025) Copyright © 2014 The Authors Terms and Conditions